The company’s lead product candidate is a potent antiparasitic drug called Artemisone. It was originally developed through a collaboration between Bayer HealthCare AG and the Hong Kong University of Science and Technology. Artemisone has been studied in multiple Phase 1 clinical trials and a 95-patient Phase 2 clinical trial as a treatment for malaria. A subsequent discovery of Artemisone as an antiviral was patented by Hadassah Medical Center in Israel and licensed to Artemis in 2016. Based on preliminary clinical results with a related compound, Artemisone is currently undergoing preclinical evaluation of its activity against cytomegalovirus (CMV), to assess its potential for both immunocompromised and congenital CMV patients.